title: Targeting therapy to the neuromuscular junction: proof of concept.
abstract: BACKGROUND
  The site of pathology in myasthenia gravis (MG) is the neuromuscular junction (NMJ). Our goal was to determine the ability to direct complement inhibition to the NMJ.
  
  
  METHODS
  A single-chain antibody directed against the alpha subunit of the acetylcholine receptor was synthesized (scFv-35) and coupled to decay-accelerating factor (DAF, scFv-35-DAF). scFv-35-DAF was tested in a passive model of experimentally acquired MG.
  
  
  RESULTS
  Administration of scFv-35-DAF to mice deficient in intrinsic complement inhibitors produced no weakness despite confirmation of its localization to the NMJ and no evidence of tissue destruction related to complement activation. Rats with experimentally acquired MG treated with scFV-35-DAF showed less weakness and a reduction of complement deposition.
  
  
  CONCLUSIONS
  We demonstrate a method to effectively target a therapeutic agent to the NMJ.
authors.affiliation: Department of Pharmacology and Physiology, George Washington University, Washington, DC, USA.
authors.forename: Linda L
authors.initials: LL
authors.lastname: Kusner
authors.forename: Namita
authors.initials: N
authors.lastname: Satija
authors.forename: Georgiana
authors.initials: G
authors.lastname: Cheng
authors.forename: Henry J
authors.initials: HJ
authors.lastname: Kaminski
mesh_terms: D000818:Animals; D018958:CD55 Antigens / Q000008:administration & dosage*; D016503:Drug Delivery Systems / Q000379:methods*; D051379:Mice; D020720:Myasthenia Gravis, Autoimmune, Experimental / Q000188:drug therapy* / Q000276:immunology; D009469:Neuromuscular Junction; D051381:Rats; D011950:Receptors, Cholinergic; D057127:Single-Chain Antibodies / Q000276:immunology / Q000627:therapeutic use*
chemical_list: D018958:CD55 Antigens; D011950:Receptors, Cholinergic; D057127:Single-Chain Antibodies
keywords: acetylcholine receptor; autoimmunity; complement; decay-accelerating factor; myasthenia gravis
references.citation: J Clin Invest. 1989 Jul;84(1):7-17
references.pmid: 2738160
references.citation: Ann Neurol. 1999 Oct;46(4):553-5
references.pmid: 10514090
references.citation: Ann N Y Acad Sci. 2008;1132:210-9
references.pmid: 18567870
references.citation: J Biol Chem. 1981 Aug 25;256(16):8635-45
references.pmid: 6167581
references.citation: Nature. 1987 Feb 5-11;325(6104):545-9
references.pmid: 2433596
references.citation: Exp Neurol. 2006 Dec;202(2):287-93
references.pmid: 16859686
references.citation: Proc Natl Acad Sci U S A. 1983 Jul;80(13):4089-93
references.pmid: 6575398
references.citation: Nature. 1977 May 19;267(5608):263-5
references.pmid: 865619
references.citation: Methods Enzymol. 1981;74 Pt C:432-60
references.pmid: 7321891
references.citation: Handb Clin Neurol. 2008;91:27-101
references.pmid: 18631840
references.citation: Nat Biotechnol. 2007 Nov;25(11):1265-75
references.pmid: 17989689
references.citation: J Neuroimmunol. 2008 Feb;194(1-2):89-96
references.pmid: 18178258
references.citation: Lancet Neurol. 2009 May;8(5):475-90
references.pmid: 19375665
references.citation: Mol Immunol. 2004 Feb;40(13):911-9
references.pmid: 14725787
references.citation: J Clin Immunol. 2010 May;30 Suppl 1:S97-102
references.pmid: 20387102
references.citation: Isr Med Assoc J. 2008 Jan;10(1):58-60
references.pmid: 18300576
references.citation: J Exp Med. 1984 Nov 1;160(5):1558-78
references.pmid: 6238120
references.citation: J Neuroimmunol. 1996 Dec;71(1-2):173-7
references.pmid: 8982117
references.citation: J Autoimmun. 2011 Sep;37(2):136-43
references.pmid: 21636248
references.citation: Brain. 2005 Oct;128(Pt 10):2327-37
references.pmid: 16150851
references.citation: Eur J Immunol. 1992 Sep;22(9):2449-52
references.pmid: 1516631
references.citation: Clin Exp Immunol. 2000 May;120(2):363-8
references.pmid: 10792389
references.citation: J Biol Chem. 2001 Jul 20;276(29):27290-5
references.pmid: 11352906
references.citation: Muscle Nerve. 2013 Jul;48(1):76-84
references.pmid: 23512355
references.citation: J Clin Invest. 2002 Nov;110(9):1269-74
references.pmid: 12417565
references.citation: Proc Natl Acad Sci U S A. 1987 Apr;84(7):2007-11
references.pmid: 2436222
references.citation: Muscle Nerve. 2000 Apr;23(4):453-77
references.pmid: 10716755
references.citation: Lab Invest. 2002 May;82(5):563-9
references.pmid: 12003997
references.citation: J Exp Med. 1989 Sep 1;170(3):637-54
references.pmid: 2475570
references.citation: Nat Biotechnol. 2007 Nov;25(11):1256-64
references.pmid: 17989688
references.citation: Muscle Nerve. 2012 May;45(5):668-675
references.pmid: 22499093
references.citation: J Immunol. 1990 Mar 1;144(5):1823-8
references.pmid: 2307842
references.citation: Nature. 1980 May 22;285(5762):238-40
references.pmid: 6154894
references.citation: Clin Exp Immunol. 2006 Nov;146(2):294-302
references.pmid: 17034582
references.citation: Adv Exp Med Biol. 2013;735:301-313
references.pmid: 22990712
references.citation: J Exp Med. 1986 Apr 1;163(4):837-55
references.pmid: 3950547
references.citation: J Virol. 2010 Apr;84(7):3210-9
references.pmid: 20071581
references.citation: Autoimmunity. 2010 Aug;43(5-6):428-35
references.pmid: 20166870
references.citation: Ann N Y Acad Sci. 2008;1132:244-8
references.pmid: 18567875
references.citation: Am J Hematol. 2009 Feb;84(2):65-70
references.pmid: 19051264
references.citation: Muscle Nerve. 2013 Jan;47(1):33-40
references.pmid: 23042232
references.citation: Semin Neurol. 2004 Mar;24(1):5-16
references.pmid: 15229787
references.citation: J Clin Invest. 2006 Nov;116(11):2843-54
references.pmid: 17080188
references.citation: Proc Natl Acad Sci U S A. 1978 Jul;75(7):3422-6
references.pmid: 277944
references.citation: Expert Rev Clin Immunol. 2008 Jan;4(1):43-52
references.pmid: 20477586